Paul Tudor Jones Ocular Therapeutix, Inc Transaction History

Tudor Investment Corp Et Al

$15.5 Billion
Q1 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 74,531 shares of OCUL stock, worth $488,923. This represents 0.0% of its overall portfolio holdings.

Number of Shares

74,531

Previous 138,731 46.28%

Holding current value

$488,923

Previous $618,000 9.71%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$3.85 - $10.93 $247,170 - $701,706	-64,200 Reduced 46.28%	74,531 $678,000
Q4 2023 Feb 14, 2024	SELL	$2.08 - $4.52 $73,706 - $160,170	-35,436 Reduced 20.35%	138,731 $618,000
Q3 2023 Nov 15, 2023	SELL	$3.14 - $5.04 $83,762 - $134,447	-26,676 Reduced 13.28%	174,167 $546,000
Q2 2023 Aug 14, 2023	BUY	$4.6 - $7.64 $609,311 - $1.01 Million	132,459 Added 193.7%	200,843 $1.04 Million
Q1 2023 May 15, 2023	SELL	$2.79 - $6.27 $86,361 - $194,081	-30,954 Reduced 31.16%	68,384 $360,000

Q4 2022 Feb 14, 2023	BUY	$2.61 - $4.41 $98,039 - $165,652	37,563 Added 60.81%	99,338 $279,000
Q3 2022 Nov 14, 2022	BUY	$4.09 - $6.5 $43,910 - $69,784	10,736 Added 21.03%	61,775 $256,000
Q2 2022 Aug 15, 2022	BUY	$3.01 - $5.22 $153,627 - $266,423	51,039 New	51,039 $205,000
Q1 2022 May 16, 2022	SELL	$4.83 - $7.35 $197,967 - $301,254	-40,987 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$6.16 - $12.07 $330,946 - $648,460	-53,725 Reduced 56.72%	40,987 $286,000
Q3 2021 Nov 15, 2021	BUY	$9.7 - $14.34 $918,706 - $1.36 Million	94,712 New	94,712 $947,000

Others Institutions Holding OCUL

# of Institutions

149

Shares Held

123M

Call Options Held

185K

Put Options Held

507K

View Full List

About OCULAR THERAPEUTIX, INC

Ticker OCUL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,966,896
Market Cap $505M
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...

More about OCUL

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account